The GMP inspection was conducted from 13 November 2024 to 19 November 2024. The USFDA issued Form-483 with 7 observations.
Dr Reddy's Labs is engaged in providing medicines. The firm operates in three segments: global generics, pharmaceutical services and active ingredients (PSAI) and proprietary products.
The company’s consolidated net profit declined 15.3% to Rs 1255.70 crore despite of 16.5% jump in revenue from operations to Rs 8016.10 crore in Q2 FY25 over Q2 FY24.
The scrip rose 1.73% to settle at Rs 1213.95 on Tuesday, 19 November 2024. The market will remain shut today on account of Maharashtra Assembly polls.